Stockreport

Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies

SUNESIS PHARMACEUTICALS  (SNSS) 
Last sunesis pharmaceuticals earnings: 3/10 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.sunesis.com/investor-overview
PDF - 50 mg Cohort Completed - - Clinical Update Expected in the Second Quarter of 2019 - SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmac [Read more]